Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

information fournie par Boursorama CP •08/01/2024 à 17:45

Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024
to further demonstrate the potential of TG4050
as an adjuvant treatment of head and neck cancers

Strasbourg, France & Tokyo, Japan, January 8, 2024, 5:45 p.m. CET/January 9,, 2024, 09:00 a.m. JST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, have announced the signing of a further development collaboration agreement to continue the clinical evaluation of the individualized neoantigen cancer vaccine TG4050.

.../...